Phase 2
It earned the FDA’s green light after its Phase II innovaTV 204 clinical trial delivered stellar results in terms of tumor response and durability of the response.
The Phase II/III trial showed a favorable safety profile and “robust” neutralizing antibody responses in children five to 11 years old who received two 10 µg doses of the vaccine at 21 days apart.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
Biopharma companies big and small are presenting exciting clinical studies at the European Society for Medical Oncology Congress 2021.
The FDA’s IND approval sets the stage for the very first Phase I/II trial to evaluate EBT-101 as a functional cure for chronic HIV based on the endpoints of safety, tolerability, and efficacy.
The company indicates that the overall data from the vixotrigine program will help them determine dose levels for future Phase III trials.
Brukinsa was approved for MSL patients who have received at least one anti-CD20-based regimen.
NovoCure and Roche aim to explore the combined efficacy of TTFields with atezolizumab as a potential treatment for pancreatic cancer.
The Phase II study showed enhanced immune memory response to the virus in 96% of vaccinated subjects, all of whom were exposed to an environment dominated by the delta variant.
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
PRESS RELEASES